Ticlatone

Ticlatone

SCHEMBL910248

Oc1nsc2cc(Cl)ccc12

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP3A4 P08684 4/20 0.40
TSHR P16473 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
BCKDK O14874 1/20 0.40
MCL1 Q07820 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 2/20 0.36
GFER P55789 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.33
HPGD P15428 4/20 0.33
ALOX12 P18054 3/20 0.33
ALOX15 P16050 3/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL911437 0.84 CYP2A6 (0.40) ALDH1A1HSD17B10CYP3A4TSHRTDP1
SCHEMBL8388159 0.79 KDM4E (0.42) ALDH1A1HSD17B10CYP3A4TSHRTDP1
SCHEMBL21609563 0.76 ALOX15 (0.35) CYP3A4ALOX15EPAS1NPC1RAB9A
SCHEMBL10222167 0.76 CYP2A6 (0.40) ALDH1A1TSHRBCKDKMCL1RXFP1
SCHEMBL22804978 0.76 BCKDK (0.40) ALDH1A1HSD17B10CYP3A4BCKDKMCL1
SCHEMBL12665748 0.76 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP3A4TSHRTDP1
SCHEMBL493085 0.76 TDP1 (0.37) ALDH1A1HSD17B10CYP3A4TSHRTDP1
SCHEMBL11451826 0.75 HSD17B10 (0.32) ALDH1A1HSD17B10CYP3A4TSHRHPGD
SCHEMBL492471 0.74 MCL1 (0.50) ALDH1A1CYP3A4TSHRBCKDKMCL1
SCHEMBL29496851 0.71 GRM4 (0.46) TSHRMEN1KMT2AMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 US disclosed
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 US disclosed
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 US disclosed
EP-1934212-A1 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-06-25 EP disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 US disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 US disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 US disclosed
WO-2007039563-A1 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-04-12 WO disclosed
WO-2007039563-A1 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives AZI2, TPMT, TET3 ALDH1A1 441/4885HSD17B10 943/4885CYP3A4 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.